Form 8-K - Current report:
SEC Accession No. 0001213900-25-044824
Filing Date
2025-05-16
Accepted
2025-05-16 14:58:06
Documents
16
Period of Report
2025-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0241550-8k_pmgc.htm   iXBRL 8-K 35936
2 SECOND AMENDMENT TO LICENSE AGREEMENT BETWEEN NORTHSTRIVE BIOSCIENCES INC. AND M ea024155001ex10-1_pmgc.htm EX-10.1 14361
3 BINDING TERM SHEET BETWEEN NORTHSTRIVE BIOSCIENCES INC. AND MODULANT BIOSCIENCES ea024155001ex10-2_pmgc.htm EX-10.2 36351
4 PRESS RELEASE DATED AS OF MAY 13, 2025. ea024155001ex99-1_pmgc.htm EX-99.1 11946
  Complete submission text file 0001213900-25-044824.txt   295685

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE elab-20250512.xsd EX-101.SCH 3026
6 XBRL LABEL FILE elab-20250512_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE elab-20250512_pre.xml EX-101.PRE 22366
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0241550-8k_pmgc_htm.xml XML 3797
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 888-445-4886
PMGC Holdings Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 25958536
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)